IE58488B1 - Vaccinal polypeptides - Google Patents
Vaccinal polypeptidesInfo
- Publication number
- IE58488B1 IE58488B1 IE210385A IE210385A IE58488B1 IE 58488 B1 IE58488 B1 IE 58488B1 IE 210385 A IE210385 A IE 210385A IE 210385 A IE210385 A IE 210385A IE 58488 B1 IE58488 B1 IE 58488B1
- Authority
- IE
- Ireland
- Prior art keywords
- polypeptide
- subunit
- protein
- fused
- coding sequence
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 63
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 62
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 62
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 35
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 32
- 230000002163 immunogen Effects 0.000 claims abstract description 30
- 241000712461 unidentified influenza virus Species 0.000 claims abstract description 27
- 230000004224 protection Effects 0.000 claims abstract description 6
- 108091026890 Coding region Proteins 0.000 claims description 30
- 101710128560 Initiator protein NS1 Proteins 0.000 claims description 25
- 101710144127 Non-structural protein 1 Proteins 0.000 claims description 25
- 229960005486 vaccine Drugs 0.000 claims description 25
- 150000001413 amino acids Chemical class 0.000 claims description 20
- 108020004414 DNA Proteins 0.000 claims description 12
- 102000053602 DNA Human genes 0.000 claims description 10
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims description 9
- 230000028993 immune response Effects 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 208000015181 infectious disease Diseases 0.000 claims description 7
- 241001465754 Metazoa Species 0.000 claims description 6
- 241000588724 Escherichia coli Species 0.000 claims description 5
- 244000005700 microbiome Species 0.000 claims description 5
- 230000004936 stimulating effect Effects 0.000 claims description 5
- 239000013604 expression vector Substances 0.000 claims description 3
- 108020001507 fusion proteins Proteins 0.000 claims description 3
- 102000037865 fusion proteins Human genes 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 claims 3
- 230000009385 viral infection Effects 0.000 abstract description 4
- 101710154606 Hemagglutinin Proteins 0.000 description 23
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 23
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 23
- 101710176177 Protein A56 Proteins 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 19
- 235000018102 proteins Nutrition 0.000 description 17
- 241000700605 Viruses Species 0.000 description 16
- 239000013612 plasmid Substances 0.000 description 15
- 239000000185 hemagglutinin Substances 0.000 description 13
- 239000000427 antigen Substances 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 10
- 229940024606 amino acid Drugs 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 210000004989 spleen cell Anatomy 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 239000008188 pellet Substances 0.000 description 9
- 239000012634 fragment Substances 0.000 description 8
- 238000003556 assay Methods 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 230000005867 T cell response Effects 0.000 description 5
- 239000013599 cloning vector Substances 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 238000000527 sonication Methods 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 3
- 108010006232 Neuraminidase Proteins 0.000 description 3
- 102000005348 Neuraminidase Human genes 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 108700010900 influenza virus proteins Proteins 0.000 description 3
- 239000011236 particulate material Substances 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 229940009976 deoxycholate Drugs 0.000 description 2
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000002480 immunoprotective effect Effects 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 241000125205 Anethum Species 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 101100137171 Drosophila melanogaster PolI gene Proteins 0.000 description 1
- 101710204837 Envelope small membrane protein Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000712469 Fowl plague virus Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000197306 H1N1 subtype Species 0.000 description 1
- 101150039660 HA gene Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000926206 Homo sapiens Putative glutathione hydrolase 3 proenzyme Proteins 0.000 description 1
- 229940124873 Influenza virus vaccine Drugs 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101150033828 NS1 gene Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 102100034060 Putative glutathione hydrolase 3 proenzyme Human genes 0.000 description 1
- 101710088839 Replication initiation protein Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 108010052915 acetyl-arginyl-arginyl-methionyl-tyrosyl-arginyl-arginyl-isoleucyl-tyrosyl-arginyl-argininamide Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229940001442 combination vaccine Drugs 0.000 description 1
- 238000011217 control strategy Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 201000010740 swine influenza Diseases 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64573284A | 1984-08-30 | 1984-08-30 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE852103L IE852103L (en) | 1986-02-28 |
| IE58488B1 true IE58488B1 (en) | 1993-09-22 |
Family
ID=24590246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE210385A IE58488B1 (en) | 1984-08-30 | 1985-08-27 | Vaccinal polypeptides |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP0176493B1 (h) |
| JP (1) | JPS6169731A (h) |
| KR (1) | KR860001882A (h) |
| AR (1) | AR241713A1 (h) |
| AT (1) | ATE63462T1 (h) |
| AU (1) | AU592954B2 (h) |
| DE (1) | DE3582843D1 (h) |
| DK (1) | DK389085A (h) |
| ES (1) | ES8800358A1 (h) |
| FI (1) | FI85811C (h) |
| GR (1) | GR852079B (h) |
| HU (1) | HU196131B (h) |
| IE (1) | IE58488B1 (h) |
| IL (1) | IL76236A0 (h) |
| NO (1) | NO169819C (h) |
| NZ (1) | NZ213249A (h) |
| PH (1) | PH27147A (h) |
| PT (1) | PT81061B (h) |
| ZA (1) | ZA856467B (h) |
| ZW (1) | ZW13485A1 (h) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4803072A (en) * | 1986-09-10 | 1989-02-07 | Smithkline Beckman Corporation | Immunomodulation |
| NZ219515A (en) | 1987-02-10 | 1989-09-27 | Wellcome Found | Fusion proteins comprising influenza virus ha and a nonnatural antigenic epitope |
| AU640348B2 (en) * | 1988-08-31 | 1993-08-26 | Smithkline Beecham Corporation | Vaccinal Polypeptides |
| DK425789A (da) * | 1988-08-31 | 1990-03-01 | Smithkline Beecham Corp | Vaccinale polypeptider |
| ZA896625B (en) * | 1988-08-31 | 1990-09-26 | Smithkline Beecham Corp | Vaccinal polypeptides |
| US5766601A (en) * | 1990-08-08 | 1998-06-16 | University Of Massachusetts Medical Center | Cross-reactive influenza a immunization |
| WO1992002250A1 (en) * | 1990-08-08 | 1992-02-20 | University Of Massachusetts Medical Center | Cross-reactive influenza a immunization |
| WO1994022917A1 (en) * | 1993-04-05 | 1994-10-13 | University Of Massachusetts Medical Center | Cross-reactive influenza a immunization |
| DE69929310T2 (de) | 1998-02-05 | 2006-08-03 | Glaxosmithkline Biologicals S.A. | Tumorassoziierte antigenderivate der mage-familie, nukleinsäuresequenzen die dafür kodieren, zur herstellung von fusionsproteinen und zusammensetzungen zur impfung |
| RU2164148C1 (ru) * | 2000-08-09 | 2001-03-20 | Петров Рэм Викторович | Вакцина против вируса гриппа и способ ее получения |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4357421A (en) | 1979-04-02 | 1982-11-02 | G. D. Searle & Co. | Synthetic gene coding for influenza hemagglutinin |
| IL61904A (en) * | 1981-01-13 | 1985-07-31 | Yeda Res & Dev | Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same |
| ZA836080B (en) * | 1982-08-23 | 1984-04-25 | Scripps Clinic Res | Broad spectrum influenza antisera |
| CA1340372C (en) * | 1984-07-09 | 1999-02-02 | John D. Clements | Production of e. coli lt-b enterotoxin subunit |
-
1985
- 1985-08-08 AR AR85301435A patent/AR241713A1/es active
- 1985-08-20 ZW ZW134/85A patent/ZW13485A1/xx unknown
- 1985-08-26 PH PH32694A patent/PH27147A/en unknown
- 1985-08-26 ZA ZA856467A patent/ZA856467B/xx unknown
- 1985-08-27 AU AU46685/85A patent/AU592954B2/en not_active Ceased
- 1985-08-27 DK DK389085A patent/DK389085A/da not_active Application Discontinuation
- 1985-08-27 IE IE210385A patent/IE58488B1/en not_active IP Right Cessation
- 1985-08-27 NZ NZ213249A patent/NZ213249A/xx unknown
- 1985-08-28 DE DE8585870120T patent/DE3582843D1/de not_active Expired - Fee Related
- 1985-08-28 GR GR852079A patent/GR852079B/el unknown
- 1985-08-28 EP EP85870120A patent/EP0176493B1/en not_active Expired - Lifetime
- 1985-08-28 IL IL76236A patent/IL76236A0/xx not_active IP Right Cessation
- 1985-08-28 AT AT85870120T patent/ATE63462T1/de not_active IP Right Cessation
- 1985-08-29 NO NO853400A patent/NO169819C/no unknown
- 1985-08-29 ES ES546530A patent/ES8800358A1/es not_active Expired
- 1985-08-29 FI FI853320A patent/FI85811C/fi not_active IP Right Cessation
- 1985-08-29 HU HU853286A patent/HU196131B/hu not_active IP Right Cessation
- 1985-08-30 JP JP60193013A patent/JPS6169731A/ja active Pending
- 1985-08-30 KR KR1019850006284A patent/KR860001882A/ko not_active Ceased
- 1985-08-30 PT PT81061A patent/PT81061B/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU592954B2 (en) | 1990-02-01 |
| ZA856467B (en) | 1986-07-30 |
| DK389085A (da) | 1986-03-01 |
| ZW13485A1 (en) | 1985-11-20 |
| DE3582843D1 (de) | 1991-06-20 |
| KR860001882A (ko) | 1986-03-24 |
| EP0176493A1 (en) | 1986-04-02 |
| PH27147A (en) | 1993-04-02 |
| NO169819B (no) | 1992-05-04 |
| PT81061A (en) | 1985-09-01 |
| ATE63462T1 (de) | 1991-06-15 |
| PT81061B (pt) | 1987-11-11 |
| NZ213249A (en) | 1989-03-29 |
| IE852103L (en) | 1986-02-28 |
| DK389085D0 (da) | 1985-08-27 |
| GR852079B (h) | 1985-12-23 |
| HU196131B (en) | 1988-10-28 |
| AR241713A1 (es) | 1992-11-30 |
| FI853320L (fi) | 1986-03-01 |
| ES8800358A1 (es) | 1987-11-01 |
| EP0176493B1 (en) | 1991-05-15 |
| FI85811B (fi) | 1992-02-28 |
| NO853400L (no) | 1986-03-03 |
| FI85811C (fi) | 1992-06-10 |
| JPS6169731A (ja) | 1986-04-10 |
| FI853320A0 (fi) | 1985-08-29 |
| ES546530A0 (es) | 1987-11-01 |
| HUT39362A (en) | 1986-09-29 |
| IL76236A0 (en) | 1986-01-31 |
| NO169819C (no) | 1992-08-12 |
| AU4668585A (en) | 1986-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111088283B (zh) | mVSV病毒载体及其病毒载体疫苗、一种基于mVSV介导的新冠肺炎疫苗 | |
| Neirynck et al. | A universal influenza A vaccine based on the extracellular domain of the M2 protein | |
| JP6069295B2 (ja) | 免疫組成物、免疫組成物の製造方法、疾患の治療剤または予防剤、組み替えポリペプチド、核酸配列、ベクターおよび宿主細胞 | |
| US6558673B1 (en) | Complexes of immunogens derived from RSV surface glycoprotein G covalently coupled to a support molecule | |
| KR20080091759A (ko) | 신규 식물 바이러스 입자 및 그의 불활성화 방법 | |
| Sui et al. | Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant | |
| CN113186173A (zh) | 一种基于减毒流感病毒载体的新型冠状病毒肺炎疫苗 | |
| EP0176493B1 (en) | Vaccinal polypeptides | |
| EP0366238A2 (en) | Influenza vaccinal polypeptides | |
| WO1993015763A1 (en) | Vaccinal polypeptides | |
| Kong et al. | Supplementation of H7N9 virus-like particle vaccine with recombinant epitope antigen confers full protection against antigenically divergent H7N9 virus in chickens | |
| CN103209990B (zh) | 重组流感病毒血凝素（ha）抗原蛋白和含其的疫苗 | |
| CN114316071A (zh) | 一种重组腮腺炎病毒颗粒、组合物及其用途 | |
| AU640348B2 (en) | Vaccinal Polypeptides | |
| JP7651129B2 (ja) | ウイルスの非構造タンパク質が担持された複合タンパク質単量体、当該単量体の会合体、及び当該会合体を有効成分とするコンポーネントワクチン | |
| KR20230091094A (ko) | 융합 단백질 및 백신 | |
| CN101293099B (zh) | 一种抗多种亚型禽流感病毒的多肽疫苗及其制备方法 | |
| CN111138550B (zh) | 一种重组呼吸道合胞病毒嵌合疫苗及其制备方法和应用 | |
| WO1994006468A1 (en) | Recombinant influenza virus vaccine compositions | |
| BRPI0720319A2 (pt) | "ácido nucléico isolado, polipeptídeo isolado, vetor de expressão, célula hospedeira, método para aprodução de um poliptídeo de fusão, partícula do vírus de mosaico do bambu quimérico, método para a produção de uma partícula do vírus de mosaico do bambu quimérico, composição imunogênica e método para a indução de uma imunoresposta em um indivíduo" | |
| JPH03130082A (ja) | ワクチン用ポリペプチド | |
| CN115850398A (zh) | 新型冠状病毒奥密克戎系列变异株的多肽组合物及其应用 | |
| KR20130001559A (ko) | 넓은 범위의 교차 방어능력을 갖는 신규한 보강 인플루엔자 백신 | |
| PT91600B (pt) | Processo para a preparacao de uma vacina contra o virus da gripe, contendo um polipeptido vacinal e de tal polipeptido | |
| WO1994022917A1 (en) | Cross-reactive influenza a immunization |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Patent lapsed |